SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive: The level of SETD2 in imatinib‐sensitive and imatinib‐resistant chronic myeloid leukaemia (CML) cells was examined by immunoblotting and quantitative real‐time PCR.